Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Allergan, Inc.    AGN   US0184901025

ALLERGAN, INC. (AGN)

39
Delayed Quote. Delayed Nyse - 10/23 04:02:30 pm
183.37 USD   +0.31%
3d ago Stronger oil stocks and surge in Shire lift FTSE
3d ago ALLERGAN : Valeant may up Allergan offer
3d ago Ackman, Valeant lawyers say Allergan CEO oversaw campaign to discredit V..
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Allergan, Inc. : Allergan : Studies Show Botox Treats Overactive Bladder

03/28/2012 | 09:54am US/Eastern

Allergan Inc. (AGN) filed applications with U.S. and European regulators for approval to sell Botox as a treatment for overactive bladder as two Phase III clinical trials showed the injectible neurotoxin significantly reduced urinary incontinence when compared with a placebo.

Botox is approved for both cosmetic use, such as fighting wrinkles, and for various medical issues, including urinary incontinence in patients with neurologic conditions such as spinal-cord injury and multiple sclerosis.

Allergan on Wednesday said Botox met the primary endpoints of significantly reducing urinary incontinence, or bladder leakage, episodes in patients who have an inadequate response to or are intolerant of an anticholinergic medication.

Based on the results, Allergan has submitted a supplemental biologics license application with the U.S. Food and Drug Administration and an application with European Regulatory authorities to approve the use of Botox by adult patients not managed by an anticholinergic treatment.

The drug maker has been expanding its pipeline of late, such as buying Vicept Therapeutics Inc., the developer of a cream to treat rosacea, and striking a deal with Map Pharmaceuticals Inc. (MAPP) to jointly promote Map's experimental migraine treatment Levadex.

Allergan reported last month its fourth-quarter earnings rose 6.3% as higher specialty pharmaceuticals sales contributed to a 7.1% revenue jump.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

Latest news on ALLERGAN, INC.
2d ago ALLERGAN : Patent Issued for Variable Cohesive Gel Form-Stable Breast Implant
2d ago ALLERGAN : Patent Issued for Interior Needle Stick Guard Stems for Tubes
2d ago ALLERGAN : Patent Issued for Compositions Containing Alpha-2-Adrenergic Agonist ..
2d ago ALLERGAN : Patent Issued for Biological Tissue Growth through Induced Tensile St..
2d ago ALLERGAN : Harvard Business Review Ranks David Pyott One of the Top 5 CEOs in th..
3d ago JOHN PAULSON : John Paulson's Solution To Shire Problem Probably Not Sitting Wel..
3d ago Stronger oil stocks and surge in Shire lift FTSE
3d ago ALLERGAN : Ackman, Valeant lawyers say Allergan CEO oversaw campaign to discredi..
3d ago ALLERGAN : Valeant may up Allergan offer
3d ago Ackman, Valeant lawyers say Allergan CEO oversaw campaign to discredit Valean..
Advertisement
Chart
Duration : Period :
Allergan, Inc. Technical Analysis Chart | AGN | US0184901025 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF